Stock OSE OSE IMMUNOTHERAPEUTICS
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases OSE Immunotherapeutics

Equities

OSE

FR0012127173

Real-time Euronext Paris
Other stock markets
 10:13:19 2024-05-03 am EDT 		5-day change 1st Jan Change
6.22 EUR -0.32% Intraday chart for OSE Immunotherapeutics +4.19% +45.33%
Apr. 17 OSE: licensing agreement with AbbVie enters into force CF
Apr. 17 OSE Immunotherapeutics Finalizes Drug License, Collaboration Deal With AbbVie MT

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
OSE Immunotherapeutics Global License to Develop a Novel Monoclonal Antibody for the Treatment of Chronic Inflammation Becomes Effective
AQ
OSE Immunotherapeutics’ Global License to Develop a Novel Monoclonal Antibody for the Treatment of Chronic Inflammation Becomes Effective
GL
OSE Immunotherapeutics Receives €8.4 M in Public Funding to Support the Registration Phase 3 Clinical Trial of Cancer Vaccine Tedopi® in Lung Cancer
GL
OSE Immunotherapeutics Receives €8.4 M in Public Funding to Support the Registration Phase 3 Clinical Trial of Cancer Vaccine Tedopi® in Lung Cancer
AQ
OSE Immunotherapeutics Announces Peer-Reviewed Publication on Novel Myeloid Immune Checkpoint CLEC-1 in Journal of Immunology
GL
OSE Immunotherapeutics Reports Full Year 2023 Financial Results and Provides Business Strategy Update
BU
OSE Immunotherapeutics Reports Full Year 2023 Financial Results and Provides Business Strategy Update
GL
OSE Immunotherapeutics : Inside Information / Other news releases
PU
OSE Immunotherapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial Evaluating Lusvertikimab in Patients with Ulcerative Colitis
BU
AbbVie and OSE Immunotherapeutics Announce Partnership to Develop a Novel Monoclonal Antibody for the Treatment of Chronic Inflammation
AQ
OSE Immunotherapeutics Highlights Clinical Portfolio Advancements and Provides 2024 Outlook
AQ
OSE Immunotherapeutics and Nantes University Hospital Present Positive Interim Data Analysis from the FIRsT Phase Study Evaluating FR104/VEL-101 Immunotherapy in Renal transplant
AQ
Neoantigen-Based Personalized Cancer Therapeutic Vaccines Pipeline, Clinical Trials Studies, Emerging Drugs, Mergers and Acquisition, Licensing, Agreements & Collaborations, and Latest News 2023
AQ
OSE Immunotherapeutics Announces a Collaboration Agreement with GenDx for the Development of a Companion Diagnostic for Epitope-Based Cancer Vaccine Candidate Tedopi
AQ
OSE Immunotherapeutics presents the first positive clinical results of its anti-PD1 monoclonal antibody OSE-279 evaluated in advanced solid tumors
AQ
OSE Immunotherapeutics Updates on its Research Programs in Presentations Selected for Upcoming International Conferences International CICON Conference SITC Annual Meeting PEGS Europe Summit
AQ
OSE Immunotherapeutics Announces, Positive Phase 3 Data from its Cancer Vaccine in Lung Cancer Patients with Resistance to Previous Immunotherapy Published in Annals of Oncology
AQ
OSE Immunotherapeutics Announces New Public Grant to Support Innovation and Research Programs in the Field of RNA Therapeutics
AQ
OSE Immunotherapeutics : 02/08/2023 OSE Immunotherapeutics Announces New Public Grant to Support Innovation and Research Programs in the Field of RNA Therapeutics
PU
OSE Immunotherapeutics : 2023 2022 Universal registration document
PU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. OSE Stock
  4. News OSE Immunotherapeutics
  5. Press Releases